p38 MAPK drives epigenetic activation of fibrotic genes in lung fibroblasts

A new research paper was published in Volume 18 of Aging-US on March 3, 2026, titled "P38 MAPK is involved in epigenetic regulation of fibrotic genes in replication induced senescence in lung fibroblasts."

Led by Shan Zhu - with corresponding author Yan Y Sanders from the Department of Biomedical and Translational Sciences, Eastern Virginia Medical School (Macon & Joan Brock Virginia Health Sciences at Old Dominion University) - the study examines how the stress-activated kinase p38 MAPK contributes to persistent profibrotic gene expression in replicative (passage-driven) senescence of human lung fibroblasts and in primary fibroblasts from patients with idiopathic pulmonary fibrosis (IPF). 

Using IMR90 lung fibroblasts at low and high population-doubling levels and primary IPF fibroblasts, the authors show that TGF-β1 upregulates profibrotic genes (α-SMA and Col3A1) in both young and near-senescent cells, but that high-PDL (near-senescent/senescent) fibroblasts exhibit a delayed but sustained p38 MAPK response to TGF-β1. Pharmacological inhibition of p38 MAPK (SB202190) blunted profibrotic transcription and reduced H4K16 acetylation (H4K16ac) enrichment at α-SMA and Col3A1 promoters, indicating an epigenetic mechanism linking p38 signaling to fibrotic gene activation. 

"These findings suggest that a p38 MAPK–dependent epigenetic mechanism is involved in fibroblast activation, supporting the therapeutic potential of p38 MAPK inhibition for treating age-related fibrotic diseases such as IPF."

The authors place these molecular results in a clinical context: persistent fibroblast activation and senescence are features of IPF and other age-associated fibrotic disorders, and the data here support targeting p38 MAPK to interrupt an epigenetically reinforced profibrotic program. The study used multiple readouts (western blot, RT-qPCR, ChIP for H4K16ac) and included primary IPF cells to strengthen translational relevance, while also noting that further work is required to test safety and efficacy in vivo.

The paper outlines clear next steps: determine the upstream triggers that sustain p38 signaling in near-senescent fibroblasts, map the chromatin-level events downstream of p38 that maintain H4K16ac at profibrotic promoters, and evaluate p38 inhibition in animal models of age-related pulmonary fibrosis. The authors also recommend exploring whether epigenetic modulators that reverse H4K16ac enrichment can synergize with kinase inhibition to restore repair capacity without impairing normal tissue healing.